AcuCort publishes newsletter with CEO update

AcuCort has published its April 2026 newsletter. The newsletter includes a CEO statement from Jonas Jönmark, in which he comments on the agreement with the FDA regarding the company’s iPSP.

The newsletter is available here: https://bit.ly/42929Pl


For further information: 
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se


About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

Läs mer på Cision

Ämnen i artikeln


AcuCort

Senast

0,83

1 dag %

4,27%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån